AI Article Synopsis

  • Juvenile myelomonocytic leukemia (JMML) is a rare blood disorder often linked to specific genetic abnormalities, and this case highlights an unusual occurrence of hemophagocytic lymphohistiocytosis (HLH) triggered by JMML with chromosome 5 abnormalities.
  • The patient, initially diagnosed with JMML at six years old after showing symptoms like hepatosplenomegaly and anemia, underwent chemotherapy but then developed HLH, complicating treatment efforts.
  • Despite some treatment response, the child ultimately experienced severe complications, and parents chose to discontinue treatment, leading to the patient's death from intracranial hemorrhage three months post-diagnosis.

Article Abstract

Rationale: Juvenile myelomonocytic leukemia (JMML) is a rare hematopoietic disorder, which is more rarely accompanied by monosomy 5 or deletion of the long arm of chromosome 5q (-5/5q-) or monosomy 5 (5q-/-5), and hemophagocytic lymphohistiocytosis (HLH) is a rare, uncontrolled hyperinflammation condition, which is more rarely secondary to JMML. Up to now, only a few cases of JMML with -5/5q- and HLH secondary to JMML were described. Here we described an extremely rare case of HLH second to JMML with 5q-.

Patient Concerns: The patient had multiple cafe-au-lait-spots at birth and was found that NF1 gene mutation was positive. At his 6 years old, he developed hepatosplenomegaly, anemia, thrombocytopenia, monocyte count 4.12×109/L in peripheral blood, 13% blasts in peripheral blood, and 11% blasts in bone marrow, without BCR/ABL rearrangement, combining with positive NF1 gene mutation, he was diagnosed as JMML. In the bone marrow, there was chromosomal abnormalities with -5/5q-. In the treatment, HLH occurred.

Diagnoses: The patient was diagnosed as secondary HLH to JMML.

Interventions: The patient received the chemotherapy treatment of the improved diffuse alveolar hemorrhage protocol, and meanwhile, he prepared for hematopoietic stem cell transplantation. Then on the basis of anti-infection, symptomatic and supportive therapy, he was commenced the treatment according to the HLH-2004 protocol.

Outcomes: He had a partial response, manifesting that his fever resolved, but the blood coagulation function did not improve, and the severe thrombocytopenia remained. Then, the parents refused the continual treatment, and the child died of intracranial hemorrhage 3 months after the diagnosis of JMML.

Lessons: JMML and HLH were relatively easy to diagnose based on clinical and laboratory results. Due to the low incidence of JMML with -5/5q- and HLH secondary to JMML, no clinical practice guidelines for the treatment of the disease have been established yet. The clinical data of a case of HLH secondary to JMML with 5q- were analyzed, and relevant studies were studied.

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000002273DOI Listing

Publication Analysis

Top Keywords

secondary jmml
16
hlh secondary
12
jmml
10
hemophagocytic lymphohistiocytosis
8
juvenile myelomonocytic
8
myelomonocytic leukemia
8
hlh
8
jmml -5/5q-
8
-5/5q- hlh
8
case hlh
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!